BR112022011099A2 - Tratamento de doenças relacionadas ao vírus da hepatite b - Google Patents

Tratamento de doenças relacionadas ao vírus da hepatite b

Info

Publication number
BR112022011099A2
BR112022011099A2 BR112022011099A BR112022011099A BR112022011099A2 BR 112022011099 A2 BR112022011099 A2 BR 112022011099A2 BR 112022011099 A BR112022011099 A BR 112022011099A BR 112022011099 A BR112022011099 A BR 112022011099A BR 112022011099 A2 BR112022011099 A2 BR 112022011099A2
Authority
BR
Brazil
Prior art keywords
hepatitis
hbv
virus
treatment
epitopes
Prior art date
Application number
BR112022011099A
Other languages
English (en)
Inventor
Ingrid Buschow Sonja
Theodora Antonetta De Beijer Monica
Bernardina Johanna Molenaar Miranda
Johannes Maria Beenakker Thomas
Johannes Theodorus Alexander Krebber Wilhelmus
Johannes Maria Melief Cornelis
Wiekmeijer Anna-Sophia
Van Rijn Peter
Talia Satirah Ludovica Jansen Diahann
Johannes Elisabeth Van Esch Wilhelmus
Original Assignee
Isa Pharmaceuticals B V
Univ Erasmus Med Ct Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V, Univ Erasmus Med Ct Rotterdam filed Critical Isa Pharmaceuticals B V
Publication of BR112022011099A2 publication Critical patent/BR112022011099A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

TRATAMENTO DE DOENÇAS RELACIONADAS AO VÍRUS DA HEPATITE B. A invenção fornece novos peptídeos imunogênicos derivados da proteína X e da proteína da polimerase do vírus da hepatite B (HBV). Os peptídeos contêm epítopos que são bem conservados em várias variantes do HBV e são derivados de regiões de proteínas que são essenciais para a replicação viral. Além disso, foram identificados os novos antígenos do HBV se ligam a vários tipos de HLA e epítopos que provocam respostas de IFN¿ em PBMCs de resolvedores de HBV.
BR112022011099A 2019-12-07 2020-12-04 Tratamento de doenças relacionadas ao vírus da hepatite b BR112022011099A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214315 2019-12-07
PCT/EP2020/084636 WO2021110919A1 (en) 2019-12-07 2020-12-04 Treatment of diseases related to hepatitis b virus

Publications (1)

Publication Number Publication Date
BR112022011099A2 true BR112022011099A2 (pt) 2022-08-23

Family

ID=68835054

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011099A BR112022011099A2 (pt) 2019-12-07 2020-12-04 Tratamento de doenças relacionadas ao vírus da hepatite b

Country Status (9)

Country Link
US (1) US20230242590A1 (pt)
EP (1) EP4069271A1 (pt)
JP (1) JP2023505304A (pt)
KR (1) KR20220143812A (pt)
CN (1) CN115003685A (pt)
AU (1) AU2020397499A1 (pt)
BR (1) BR112022011099A2 (pt)
CA (1) CA3160755A1 (pt)
WO (1) WO2021110919A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240029765A (ko) 2021-07-12 2024-03-06 아이에스에이 파마슈티컬즈 비.브이. 복잡한 혼합물에서의 개선된 물질 정량화
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种鼻咽癌患病风险预测试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
AUPO351996A0 (en) * 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
ATE502952T1 (de) 2000-09-01 2011-04-15 Epimmune Inc Hla-bindungspeptide und ihre anwendungszwecke
BR0017332A (pt) 2000-09-08 2003-10-07 Epimmune Inc Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico
WO2007110098A1 (en) * 2006-03-29 2007-10-04 Institut National De La Sante Et De La Recherche Medicale HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV
WO2011015656A2 (en) 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines

Also Published As

Publication number Publication date
JP2023505304A (ja) 2023-02-08
US20230242590A1 (en) 2023-08-03
CA3160755A1 (en) 2021-06-10
CN115003685A (zh) 2022-09-02
WO2021110919A1 (en) 2021-06-10
KR20220143812A (ko) 2022-10-25
AU2020397499A1 (en) 2022-06-16
EP4069271A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
BR112022011099A2 (pt) Tratamento de doenças relacionadas ao vírus da hepatite b
BR112018002406A2 (pt) anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos
PH12021550580A1 (en) African swine fever virus vaccine
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
UY27840A1 (es) Vacunas
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
EA202092828A1 (ru) Антигенный вариант вируса varicella zoster и его применение
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112022024063A2 (pt) Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina
BR112023001500A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno hla-g e usos dos mesmos
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
BR112022003474A2 (pt) Vacinas do vírus da hepatite b
MX2017011732A (es) Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
BR112018000037A2 (pt) partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina
BR112022010425A2 (pt) Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
ES2085163T3 (es) Vacunas contra los parasitos metazoos.